(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Biorestorative Therapies's earnings in 2026 is -$11,056,581.On average, 4 Wall Street analysts forecast BRTX's earnings for 2026 to be -$12,863,923, with the lowest BRTX earnings forecast at -$16,479,274, and the highest BRTX earnings forecast at -$8,828,182. On average, 4 Wall Street analysts forecast BRTX's earnings for 2027 to be -$10,525,028, with the lowest BRTX earnings forecast at -$12,983,670, and the highest BRTX earnings forecast at -$7,758,100.
In 2028, BRTX is forecast to generate -$10,654,967 in earnings, with the lowest earnings forecast at -$12,234,612 and the highest earnings forecast at -$8,828,182.